Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18791377 | 0.78 | DAO (0.34) | MAPTDAOAXLPRKCIHTT | |
| SCHEMBL12503575 | 0.75 | MGMT (0.35) | MAPTDAOAXLPRKCIKMT2A | |
| SCHEMBL19216519 | 0.75 | MAPT (0.41) | MAPTCYP2A6PDE3BPDE3AHTT | |
| SCHEMBL24271306 | 0.75 | PLAU (0.33) | — | |
| SCHEMBL23323388 | 0.72 | — | — | |
| SCHEMBL12051931 | 0.71 | RXFP1 (0.36) | MAPTHTTKMT2ALMNA | |
| SCHEMBL2762630 | 0.70 | — | — | |
| SCHEMBL2232005 | 0.70 | — | — | |
| SCHEMBL30319394 | 0.70 | — | — | |
| SCHEMBL30605193 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289497-A1 | FUSED PYRIDINE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289497-A1 | FUSED PYRIDINE DERIVATIVES | GPR119, INSR, IAPP | MAPT 4094/4885DAO 2463/4885CYP2A6 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.